Purohit Navigation, Author at STAR Therapeutics

About Purohit Navigation

This author has not yet filled in any details.
So far Purohit Navigation has created 16 blog entries.

Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair
Gallery
Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair

Press Release

Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair

SOUTH SAN FRANCISCO, CA, December 5, 2023 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

By Purohit Navigation|2023-12-05T09:51:39-05:00December 5, 2023|Press Release|0 Comments

Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies
Gallery
Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

Press Release

Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...

By Purohit Navigation|2023-09-04T22:05:36-04:00September 5, 2023|Press Release|0 Comments

Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
Gallery
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

Press Release

Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...

By Purohit Navigation|2023-05-22T22:49:30-04:00May 23, 2023|Press Release|0 Comments

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease
Gallery
Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease

Press Release

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease

Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...

By Purohit Navigation|2023-05-05T09:50:48-04:00April 6, 2023|Press Release|0 Comments

Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting
Gallery
Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting

Press Release

Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting

By Purohit Navigation|2023-05-05T09:49:19-04:00December 6, 2022|Press Release|0 Comments

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies
Gallery
Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies

Press Release

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies

Drug discovery approach uncovers novel biology for treatments that can [...]

By Purohit Navigation|2024-06-25T15:25:02-04:00February 16, 2022|Press Release|0 Comments

Previous 12

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

About Purohit Navigation

THANK YOU